WEKO3
アイテム
Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan
http://hdl.handle.net/10069/38193
http://hdl.handle.net/10069/381938adc5c86-ea3c-4f08-8693-270170eec834
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ActMed61_167.pdf (1.0 MB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-05-10 | |||||
| タイトル | ||||||
| タイトル | Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | chronic pulmonary aspergillosis | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | liposomal amphotericin B | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | voriconazole | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 著者 |
Kohno, Shigeru
× Kohno, Shigeru× Izumikawa, Koichi× Ogawa, Kenji× Kurashima, Atsuyuki× Okimoto, Niro× Suzuki, Katsuhiro× Kakeya, Hiroshi× Niki, Yoshihito× Ichihara, Kiyoshi× Miyazaki, Yoshitsugu |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary syndrome due to infection of Aspergillus spp. We conducted a randomized, multicenter, open-label trial comparing intravenous liposomal amphotericin B (L-AMB) of 2.5-5.0 mg/kg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily. Treatment effectiveness was defined by clinical, and radiological improvement at both 2 weeks after the initial administration and at the end of therapy. The total of 166 patients were recruited and 83 patients for each drug group were assigned. Total of 51 and 59 cases of L-AMB and VRCZ, respectively were assessed as per-protocol populations. The difference in efficacy rates between L-AMB and VRCZ was not significant, either after 2 weeks [49.0% vs. 59.3%; the absolute difference, 10.3% with a 95% confidence interval (CI), -8.4 to 29.00, P=0.279] or at the end of therapy (52.9% vs. 67.8%; the absolute difference, 14.9% with a 95% CI, -3.4 to 33.2, P=0.111). In the safety evaluation, no statistical difference of occurrence rates in both LAMB and VRCZ group (54.2% vs. 59.0%, P=0.531). L-AMB was as effective as VRCZ with no significant difference of adverse effects in the treatment of CPA. (UMIN Clinical Trials Registry number, UMIN000002236.) | |||||
| 書誌情報 |
Acta medica Nagasakiensia 巻 61, 号 4, p. 167-176, 発行日 2018-03 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 00016055 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00508430 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 出版者 | ||||||
| 出版者 | Nagasaki University School of Medicine | |||||
| 出版者別言語 | ||||||
| 値 | 長崎大学医学部 | |||||
| 関係URI | ||||||
| 関連名称 | http://hdl.handle.net/10069/38673 | |||||
| sortkey | ||||||
| 値 | 05 | |||||
| 引用 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Acta medica Nagasakiensia, 61(4), pp.167-176; 2018 | |||||
